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Introduction
Chondrogenesis is the earliest phase of skeletal development, 
involving mesenchymal cell recruitment and migration, con-
densation of progenitors, and chondrocyte differentiation and 
maturation. These processes lead to the formation of cartilage 
and bone during endochondral ossification.1-3 Mutations or 
deregulation of these processes lead to skeletal malformation, 
skeletal malfunction, and/or susceptibility to injury.4
Each step of the chondrocytic differentiation process 
is characterized by specific morphological change and 
gene expression profiles. Several cytokines, growth fac-
tors, extracellular matrix (ECM) components, and tran-
scription factors have important roles in these processes. 
Two groups of transcription factors have been identified 
that control the key steps of chondrocyte differentiation: 
the Sox and Runx families.
The Sox trio of transcription factors (Sox9/Sox5/Sox6) 
has important regulatory functions in the early stages of 
chondrogenesis. Sox5 and Sox6 are coexpressed with Sox9 
in pre-chondrocytes and proliferating chondrocytes, and 
the three Sox proteins cooperate with each other to directly 
activate type II collagen (Col2a1) and aggrecan in vitro.5,6 
Sox9-null mutant cells in mouse embryo chimera are 
excluded from mesenchymal condensations and fail to 
express Col2a1 and other chondrocyte-specific markers 
(Col9a2, Col11a2, and aggrecan), indicating that Sox9 is 
required for mesenchymal condensation and subsequent 
cartilage formation.7 Sox5 and Sox6 have essential but 
somewhat redundant roles in promoting chondrogenesis, 
and double-null mice fetuses die at embryonic day 16.5 
(E16.5) from heart failure with severe chondrodysplasia.8
A key transcription factor controlling pre-hypertrophic 
and hypertrophic chondrocyte differentiation is Runx2. 
Runx2 is required for osteoblast formation but also neces-
sary for normal chondrocyte maturation. Runx2 is mainly 
expressed when chondrocytes are about to become pre-
hypertrophic, and it remains expressed through hypertro-
phy and terminal differentiation.9 Runx2-null mice have 
abnormal hypertrophic chondrocyte differentiation in addi-
tion to failure of bone formation.10,11 However, there is 
failure of terminal differentiation only in the humerus and 
femur and delayed terminal differentiation in other long 
bones, including tibia, fibula, radius, and ulna.10,12 These 
data would suggest that additional transcription factors play 
a role during terminal differentiation.2
The transcription factor c-Maf is specifically expressed 
in late hypertrophic and terminal chondrocytes,13,14 making 
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it a candidate for controlling terminal differentiation. In 
addition, the expression of c-Maf and Lc-Maf, an mRNA 
splicing variant of c-Maf, partially overlaps with the 
expression of both Sox9 and Runx2.15
c-Maf Is a bZIP Transcription Factor
The founding member of Maf family, v-Maf (muscu-
loaponeurotic fibrosarcoma), was originally identified as a 
retroviral oncoprotein, and then cellular counterparts, 
c-Mafs, were cloned from a number of vertebrate genomes.16 
The Maf family is currently subdivided into two groups, 
small Maf (MafF, MafG, MafK, MafT, and MafS) and large 
Maf (c-Maf, MafA, MafB, and Nrl [neural retina leucine 
zipper]) proteins based on their domain structure and func-
tion (Table 1). A transcript variant of c-Maf, Lc-Maf, also 
has been reported15 (Fig. 1). The large Maf proteins contain 
a conserved N-terminal transactivation domain, whereas 
the small Maf proteins lack this transactivation domain.17 
Based on the strong sequence conservation, the members of 
the Maf family are classified under the bZIP transcription 
factor superfamily.
The bZIP transcription factor superfamily consists of 
53 different proteins in humans18 and has been subdivided 
into several subgroups, including the hallmark AP-1 com-
plex (c-Fos/c-Jun), CREB/ATF, CNC, C/EBP, PAR, and 
Maf families.19 bZIP transcription factors are activated by 
a variety of signal transduction pathways to mediate criti-
cal aspects of cellular differentiation.19 The bZIP struc-
tural motif is a long bipartite α-helix of 60 to 80 amino 
acids in length and comprises a basic region and a leucine 
zipper. The N-terminal basic region contains an 18–amino 
acid basic peptide responsible for specific DNA recogni-
tion, whereas the C-terminal leucine zipper domain 
mediates homo- and heterodimerization with other bZIP 
proteins.18
The Maf family members are unique among the bZIP 
superfamily in that they contain a highly conserved ancillary 
DNA binding domain N-terminal to the typical basic domain 
(Fig. 1), which increases the number of specific DNA 
sequences that can be bound.20 Through this extended DNA 
binding domain, Maf proteins bind to relatively long consen-
sus DNA sequences termed Maf-recognition elements 
(MAREs).21 Early in vitro selection studies identified two 13– 
and 14–base pair palindromic sequences, TGCTGACTCAGCA 
(T-MARE) and TGCTGACGTCAGCA (C-MARE), as the 
optimal binding sites for c-Maf.21 The T-MARE contains a 
phorbol 12-O-tetradecanoate (TPA)–Response Element (TRE: 
TGACTCA), and the C-MARE contains a cyclic AMP-
responsive element (CRE: TGACGTCA) in the middle region, 
respectively. However, in vitro studies have shown that some 
base mismatches from the consensus sequences are allowed in 
Maf binding to the MARE and that Maf homodimers also bind 
efficiently to MARE half-palindromic sites when they are 
preceded by an AT-rich sequence.22 Naturally occurring c-Maf 
binding sites in IL-4, crystallin, and other genes are not intact 
palindromic sequences, as the full-consensus sequences are 
present only in the 5′ half-region.23 Therefore, although there 
is a degree of specificity in the Maf binding to the target DNA 
sequences, there is also considerable flexibility.
c-Maf in Chondrocytes
In the developing mouse embryo, c-Maf is strongly 
expressed in the lens fiber cells,24 and studies have 
focused on c-Maf’s function in lens development. c-Maf 
expression in chondrocytes was first reported in rat.13 
Expression of c-Maf and MafB was detected at the RNA 
level in limb and rib cartilage as well as eye lens and spi-
nal cord of the E15 rat embryo. The analysis of postnatal 
rat femur epiphysis in the same study showed that c-Maf 
is expressed strongly in the hypertrophic chondrocytes 
but low in immature proliferating chondrocytes. A detailed 
localization study in mouse embryonic cartilage showed 
that c-Maf is expressed mostly in late hypertrophic and 
terminally differentiated chondrocytes with a maximal 
expression at E15.5-E16.5 and at low levels in the peri-
chondrium and in the primary spongiosa.14 On the other 
Table 1. Binding Partners of Mafs
Mafs
Binding  
Partners References
Large Mafs
 c-Maf c-Maf Civil et al., 200270
 MafB Hale et al., 200049
 Nrl Kerppola and Curran, 199420
 Jun Kerppola and Curran, 199420
 Fos Kerppola and Curran, 199420
 TBP Friedman et al., 200432
 CBP/p300 Chen et al., 200233
 MafA MafA Benkhelifa et al., 199837
 c-Jun Benkhelifa et al., 199837
 TBP Friedman et al., 200432
 MafB c-Maf Civil et al., 200270
 MafB Kataoka et al., 199417
 Fos Kataoka et al., 199417
 Nrl c-Maf Kerppola and Curran, 199420
 Jun Kerppola and Curran, 199420
 TBP Friedman et al., 200432
Small Mafs  
 MafF MafF Kimura et al., 200771
 MafG MafG Kimura et al., 200771
 MafK MafK Kataoka et al., 199421
 MafF/MafK Fos Kataoka et al., 199572
 MafG/MafK p45NF-E2 Toki et al., 199773
 MafF Nrf1 Johnsen et al., 199674
 MafG Nrf2 Kimura et al., 200771
Homo- and heterodimers form between Mafs and other bZIP family 
proteins. Mafs also bind to general transcription factors and coactivators.
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hand, Lc-Maf is expressed in E10.5-E12.5 mesenchymal 
condensations.15 At later stages, Lc-Maf expression is 
detected only in the perichondrium, with no expression 
in differentiated chondrocytes.15 Although the differential 
expression patterns of c-Maf and Lc-Maf during chon-
drogenesis were described, the functional differences 
between c-Maf and Lc-Maf are still unknown. Thus, the 
regulation mechanisms that control temporal-spatial 
expression of the different c-Maf isoforms need to be 
further investigated.
The prominent phenotype of the c-Maf-null mice is 
defective lens fiber cell differentiation.24-26 Direct transac-
tivation of lens-specific crystallin genes by c-Maf has been 
related to this phenotype. Although c-Maf (+/–) hetero-
zygous mice have normal lenses, naturally occurring het-
erozygous point mutations in c-Maf cause mild cataracts in 
both mice and humans.27,28 These mutations in the basic 
domain may have a dominant negative effect on wild-type 
c-Maf protein. Whether these mutations are related to 
abnormal cartilage formation remains unknown. It is inter-
esting to note that lens and cartilage share similar gene 
expression profiles, especially genes involved in ECM 
such as collagens, other noncollagenous ECM proteins, 
and matrix metalloproteinases (MMPs).29,30 Hence, similar 
regulation mechanisms for gene expression may occur in 
both tissues.
The role of c-Maf in cartilage was examined in endo-
chondral bone development in mice lacking c-Maf.14 
c-Maf-null mice have abnormal terminal differentiation of 
hypertrophic chondrocytes with the most dramatic abnor-
mality at E15.5 to E16.5, which corresponds to the time 
points of the highest c-Maf expression in chondrocytes.14 
Terminal differentiation of the hypertrophic chondrocytes 
is delayed, and the domain of late hypertrophic chondro-
cytes is expanded in both the E16.5 to E18.5 embryos and 
4-week postnatal c-Maf-null mice. The expanded hyper-
trophic zone is associated with delayed vascular invasion 
and reduced ossification. This suggests that c-Maf facili-
tates both the initiation and the completion of terminal dif-
ferentiation in chondrocytes.14
Interaction of Maf Proteins with Other 
Transcription Factors
The Maf proteins dimerize with themselves and with other 
bZIP proteins through the leucine zipper domain. They can 
also interact with several non-bZIP factors.15,31-33 The Maf 
binding partners that have been identified so far are sum-
marized in Table 1, and the various types of c-Maf binding 
interactions are illustrated diagrammatically in Figure 2. 
There is specificity in Maf dimerization, and the different 
binding interactions affect the transactivation function of 
the Maf proteins. However, the circumstances that deter-
mine the binding of Maf to its partners are not fully under-
stood. The small Maf proteins, which do not dimerize with 
large Mafs, generally repress transcription when they form 
homodimers. In contrast, when they form heterodimers 
Figure 1. Schematic representation of c-Maf genomic structure and predicted functional domains. c-Maf and its RNA splice variant 
Lc-Maf (long form c-Maf) contain the same 5′ untranslated region. c-Maf is transcribed from a single exon, and through mRNA splicing, 
Lc-Maf has a frame shift that alters the last amino acid of c-Maf Exon 1 and codes for an additional 10 amino acids (in mouse) or 30 amino 
acids (in human). The mechanism of splicing is unknown. Intron/exon sizes are not drawn to scale.
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with other members of bZip proteins, they can activate or 
repress transcription of genes regulating many aspects of 
cellular differentiation.34,35 A heterodimeric partner of small 
Maf, the transcription factor nuclear factor E2 p45-related 
factor-2 (Nrf2), displays decreased expression during 
chondrocyte differentiation and inhibits numerous aspects 
of chondrocyte differentiation in vitro.36 This suggests the 
possibility that small Maf/Nrf2 heterodimers may be 
involved in the negative regulation of chondrocyte differ-
entiation, although no expression data for small Mafs are 
available in chondrocytes. Large Mafs efficiently form 
homodimers both in vitro and in vivo. They also have the 
ability to form heterodimers with AP-1 family members in 
vitro, although heterodimers have not yet been detected in 
vivo.21 In vitro, c-Maf and Nrl can form heterodimers with 
c-Fos and c-Jun.20 MafA can heterodimerize with c-Jun but 
not with c-Fos, whereas MafB can form heterodimers with 
c-Fos but not with c-Jun.37 Considering that Maf proteins 
are expressed in a wide variety of cells and tissues, it has 
been suggested that mixing and matching of dimeric part-
ners might create specific complexes within cells to affect 
target gene expression and cell differentiation.38
Mafs can also physically and/or functionally interact 
with several non-bZIP proteins, including general transcrip-
tion factors, common coactivators, and specific transcription 
factors (Fig. 2). Nrl directly interacts with TATA binding 
protein (TBP) in vitro, and TBP is co-immunoprecipitated 
with the Nrl-, c-Maf- and MafA-containing complexes 
in vivo.32 c-Maf recruits the CREB binding protein (CBP) 
and p300 to the promoters of crystallin genes, resulting in 
the synergistic activation of the genes.33 This synergistic 
activation requires histone acetyltransfease activity, indicat-
ing that chromatin remodeling is involved in c-Maf transac-
tivation. Synergy in transcriptional activation by c-Maf and 
other specific transcription factors was also observed. c-Maf 
acts synergistically with Sox1, Sox2, and Sox3, which are 
important regulators of lens development, to activate the γF-
crystallin gene.39 Similarly, Lc-Maf acts synergistically with 
Sox9 to activate the Col2a1 and type XXVII collagen 
(Col27a1) gene transcription in chondrocytes.15,40
c-Maf Target Genes and Pathways  
in Chondrocytes
Although Maf was first identified as a retroviral oncopro-
tein, the physiological functions of Maf family proteins 
include regulatory roles in a wide variety of cell- and tissue-
specific gene expression and in cell differentiation during 
development.41 The target genes of Maf transcription factors 
in tissues are well summarized (see review by Kataoka41). 
This section focuses on c-Maf targets in chondrocytes, sum-
marizing various lines of evidence that c-Maf regulates 
genes related to chondrocyte differentiation and the progres-
sion of osteoarthritis. This growing list of genes includes 
matrix metalloproteinase-13 (MMP-13), connective tissue 
growth factor (CTGF), Col2a1, and Col27a1 (Fig. 3).
MMP-13, along with other matrix metalloproteinases, 
affects hypertrophic differentiation and vascular invasion 
through matrix proteolysis.42 MMP-13 is induced in termi-
nally differentiated chondrocytes in the developing growth 
plate and is highly upregulated in osteoarthritic cartilage. 
MMP-13 expression in the hypertrophic chondrocytes region 
was decreased specifically in the c-Maf-null mice embryo,14 
suggesting a regulatory role for c-Maf in MMP-13 expres-
sion. This is supported by a study of c-Maf activity on 
the MMP-13 proximal promoter.43 However, there is the 
possibility that c-Maf indirectly regulates MMP-13 expres-
sion through the activation or repression of other factors, 
and further molecular and biological examination will be 
required.
CTGF is involved in chondrocyte differentiation 
and angiogenesis during skeletal development.44 CTGF and 
c-Maf are co-localized in hypertrophic chondrocytes, and 
interestingly, c-Maf-null and CTGF-null mice share com-
mon phenotypes, including expanded hypertrophic zones in 
the E16.5 embryo and reduced ossification of the tibia.14,44 
CTGF is expressed by proliferating and hypertrophic 
chondrocytes in the mouse growth plate,45 and it was iden-
tified as a c-Maf-responsive gene in chondrocytes.40 
In vitro studies using reporter transfection assays have 
shown that c-Maf and Lc-Maf activate the CTGF promoter, 
Figure 2. Different types of c-Maf binding interactions. c-Maf 
can form homodimers as well as heterodimers with other 
bZIP transcription factors. In addition, several factors, including 
general transcription factors (TBP), cofactors (CBP), and specific 
transcription factors (Sox9), interact with c-Maf.
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and chromatin immunoprecipitation assays demonstrated a 
direct interaction between the CTGF promoter and Maf.
Col2a1 was also upregulated by Lc-Maf via direct inter-
actions with the intronic enhancer.15 Lc-Maf interacts with 
Sox9 to synergistically activate Col2a1 transcription 
in vitro. Lc-Maf is coexpressed with Sox9 and Col2a1 in 
the precartilaginous mesenchymal condensations during 
mouse embryogenesis, suggesting a role for Lc-Maf in 
early chondrocyte differentiation. The same study identi-
fied an Lc-Maf binding site adjacent to the well-known 
Sox9 binding site, although this site does not contain the 
typical MARE consensus sequence. The timing of in vivo 
expression of the Sox proteins and Lc-Maf during chondro-
genesis led to the hypothesis that Lc-Maf cooperates early 
with Sox9 to activate target genes, including Col2a1, dur-
ing mesenchymal condensation and that Sox9/Sox5/Sox6 
function at later steps of chondrocyte differentiation.15
Col27a1 was recently identified as a target gene of 
Lc-Maf.31 Col27a1 is most abundant in proliferating and 
pre-hypertrophic chondrocytes during endochondral ossifi-
cation.46 The enhancers of Col27a1 contain a Sox9-
responsive element similar to that of Col2a1, and Lc-Maf 
and Sox9 synergistically activate the expression of both 
Col27a1 and Col2a1.15 Further evidence of the physiologi-
cal significance of this activation comes from the co- 
localization of Lc-Maf and Col27a1 in growth plate, with 
maximal expression of both genes occurring in the prolifer-
ating and pre-hypertrophic chondrocytes.31
c-Maf may be involved in chondrocyte apoptosis either 
in the normal bone formation process or in the progression 
of pathologic conditions. The targets of c-Maf in apoptosis 
pathways have been identified in nonchondrocyte cells and 
appear to be dependent on the specific cell context. It has 
been shown that c-Maf interacts with the transcription factor 
c-Myb to downregulate Bcl-2 expression and increase apop-
tosis in peripheral CD4 cells47 and that c-Maf increases 
apoptosis by direct transactivation of caspase-6 in periph-
eral CD8 cells.48 Apoptosis through a p53-dependent path-
way may also be relevant in both normal chondrocyte 
maturation and pathologic conditions. The promoter of p53 
contains MARE consensus sequences, and overexpression 
of c-Maf induces p53-dependent cell death in primary rat 
embryo fibroblast cells.49 The p53-null embryonic mice 
have defects in the skeletal growth, abnormal chondrocyte 
maturation, and abnormal chondrocyte apoptosis, suggest-
ing that p53 plays a role in normal chondrocyte develop-
ment.50 Increased expression of p53 was reported in 
rheumatoid arthritis.51,52
The target genes regulated by c-Maf and Lc-Maf, as 
well as the phenotypes of c-Maf-null mice, generate the 
general types of abnormalities commonly seen with factors 
that affect endochondral ossification or chondrocytic dif-
ferentiation. A causative role for c-Maf will require more 
hard evidence from direct experimentation.
Regulation of c-Maf
The Maf proteins control multiple biological processes, and 
they are synthesized at varying levels and in distinct spa-
tial-temporal patterns; therefore, it is important to deter-
mine how they are regulated. There must be regulation 
mechanisms that control the levels of Maf members or 
splicing variants either on mRNA and/or protein levels. 
Several upstream regulators of Maf have been identified in 
the nonchondrocyte cells, and one can speculate that simi-
lar Maf regulation exists in chondrocytes (Fig. 3).
The fibroblast growth factor (FGF) pathway is a candi-
date for regulation of c-Maf expression. FGF signaling 
plays an important role in lens fiber differentiation, which 
is severely disrupted in c-Maf-null mice.25 Deletion of three 
FGF receptors (Fgfr1-3) demonstrated that the expression 
of FGFR is required for normal lens development, and 
FGFR deletion is involved in reduced expression of c-Maf 
and its target genes, crystallins, in the lens.53 The regulation 
of Maf by FGF signaling is at the posttranslational level. 
MAPK pathway is activated upon interaction of FGFR and 
ligand, and the FGF/MAPK cascade leads to the activation 
of ERK1/2 kinases, which can phosphorylate MafA.54 Two 
conserved serine residues (Ser14 and Ser65) located in the 
Maf transactivation domains are phosphorylated by ERK. 
Figure 3. Schematics of c-Maf target genes in chondrocytes and 
possible pathways regulating c-Maf regulation. FGF/MAPK/ERK 
pathway may activate and affect the stability of c-Maf, based on 
homology with interactions affecting MafA. Some interactions 
are proposed based on homology of the phosphorylation/
ubiquitination sites between MafA and c-Maf. These interactions 
still need to be verified for c-Maf, as clarified in the text.
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These phosphorylations affect the stability of Maf and are 
required for Maf-dependent transcriptional activation.
Phosphorylation of Maf family proteins is a tightly con-
trolled regulation mechanism. The transforming activity of 
MafA is controlled by glycogen synthase kinase–3 (GSK-
3)–dependent phosphorylations, at conserved serine/threo-
nine residues that are also present on c-Maf.55 This 
phosphorylation resulted in the recruitment of coactivators 
to increase MafA-dependent transcription, and once 
released from the coactivators, the phosphorylation induced 
MafA ubiquitination and degradation. Similarly, glucocor-
ticoids can regulate c-Maf ubiquitination and proteosomal 
degradation to negatively regulate c-Maf-dependent 
 transcription, although the phosphorylation status of c-Maf 
was not examined.56 Whether these pathways regulate 
c-Maf in chondrocytes or during chondrogenic differentia-
tion remains to be determined experimentally.
Osteoarthritis and Terminal Chondrocyte 
Differentiation
Osteoarthritis (OA) is a degenerative joint disease character-
ized by erosion of the articular cartilage, hypertrophy of bone 
at the margins (i.e., osteophytes), subchondral sclerosis, and 
a range of biochemical and morphological alterations of the 
chondrocytes. Whereas endochondral ossification involves 
successive steps of chondrocyte maturation resulting in ter-
minal hypertrophy and mineralization, normal articular 
chondrocytes are constrained from further differentiation, as 
evidenced by a lack of hypertrophic marker expression.57 
However, during the progression of OA, the articular 
chondrocytes behave analogously to late hypertrophic and 
terminally differentiating growth plate chondrocytes with 
respect to their gene expression and cellular function. 
Increased expressions of hypertrophic chondrocyte markers 
and osteoblast markers occur in OA, such as type X collagen, 
osteopontin, osteocalcin, and alkaline phosphatase.58-60 
Moreover, OA chondrocytes actively produce cartilage-
degrading enzymes, including MMP-13, which is normally 
expressed only in the late hypertrophic zone,61-63 and cell 
apoptosis is also frequently observed in OA cartilage.64,65 
Thus, it has been suggested that OA may involve the func-
tional loss of mechanisms that block articular chondrocyte 
maturation.66 In this context, understanding the mechanisms 
that control chondrocyte hypertrophy is important for normal 
skeletal development and growth, as well as cartilage degen-
eration during the pathogenesis of OA.
Three studies have suggested a possible involvement of 
Mafs in the pathogenesis of OA.43,67,68 Microarray analysis 
of a rat model of OA demonstrated an upregulation of 
MafB expression in degenerating cartilage.68 It is notewor-
thy that the expression patterns of c-Maf and MafB in rat 
embryo cartilage are virtually identical.13 Expression of 
c-Maf was upregulated in OA cartilage compared to normal 
cartilage by real-time PCR and in situ hybridization.43,67 
Because it has been shown that cells in the chondrocyte 
clusters in OA have increased expression in both cartilage 
matrix proteins and matrix-degrading proteases,69 it is nota-
ble that c-Maf mRNA was detected in proliferating 
chondrocyte clusters in OA cartilage, whereas almost no 
c-Maf-positive cells were found in normal cartilage.67
Concluding Remarks
The Maf family proteins form a unique subclass of bZIP 
transcription factors. Since the identification of v-Maf, 
many aspects of the physiological roles of Maf proteins 
have been elucidated, and currently Mafs are widely 
accepted as regulators of tissue-specific gene expression 
and cell differentiation. Studies of the roles of Maf proteins 
in chondrocyte differentiation and cartilage are under way, 
as is the identification of genes directly regulated by c-Maf. 
The identification of c-Maf binding partners and additional 
target genes during chondrogenesis and OA will provide 
insight into molecular functions of c-Maf. Furthermore, 
studies to integrate upstream differentiation signal and 
modulation of c-Maf activity at specific differentiation 
steps will be important to understanding chondrocyte ter-
minal differentiation and OA pathogenesis.
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